91 results about "Immune inflammation" patented technology

The invention relates to the technical field of biomedical materials, in particular to a titanium implant multifunctional composite coating with anti-active oxygen and anti-inflammatory dual performance and a preparation method of the titanium implant multifunctional composite coating. The coating is composed of a lanthanum oxide (La2O3) nano-particle layer growing on the surface of the titanium implant in situ and queen lily glycoside A (RA) loaded on the lanthanum oxide (La2O3) nano-particle layer and can continuously release La < 3 + > and RA. The preparation method comprises the following steps: performing alkali heat treatment on the titanium substrate; a La (OH) 3 coating is synthesized on the surface in situ through a hydrothermal reaction; the La2O3 nano-particles are calcined and converted into a La2O3 nano-particle layer with a porous structure; and finally loading RA through an impregnation method. The coating can effectively remove ROS, regulate immune inflammatory response, promote osteogenic differentiation and inhibit osteoclast activity, thereby remarkably promoting osseointegration. The problem of osseointegration under the osteoporosis pathological microenvironment is effectively solved, the preparation process is simple and controllable, and the composition is suitable for bone defect repair of osteoporosis patients and has important clinical application value.

The invention discloses a therapeutic nano-vesicle preparation rich in mitochondrial functional protein, a preparation method of the therapeutic nano-vesicle preparation and application of the therapeutic nano-vesicle preparation in treatment of radioactive skin injury. The preparation method comprises the following steps: culturing, amplifying and cleaning umbilical cord mesenchymal stem cells, dispersing the umbilical cord mesenchymal stem cells in a suspension, mechanically extruding the umbilical cord mesenchymal stem cells into a crude solution through a multistage aperture polycarbonate membrane, and centrifuging, concentrating and purifying the crude solution to obtain the preparation. The preparation has the remarkable advantages that local administration can be realized, inflammation can be quickly inhibited, oxidative stress is reduced, and a repair pathway is activated, so that the preparation is suitable for treating acute radioactive skin injury; the preparation method is easy to standardize and scale, high in stability and convenient for emergency storage and delivery, and avoids the defects of cell therapy; a plurality of targets such as immune inflammation, oxidative stress and the like can be synergistically regulated, the biological effect of hUMSCs is simulated and partially replaced, and the limitation caused by the cell survival rate and the microenvironment dependency is avoided; the key function of hUMSCs is covered in function, and the clinical feasibility, safety and emergency suitability of the application level are higher.

The invention provides a composite nanoparticle with active substance sequential release capability, a multifunctional microneedle patch based on curcumin-loaded ZIF-67 nanoparticles, preparation methods of the composite nanoparticle and the multifunctional microneedle patch and application of the multifunctional microneedle patch, and belongs to the technical field of biology. The composite nano-particles with the active substance sequential release capability are CurZIF-67NPs, the average particle size is 403 + / -7 nm, the microstructure is dodecahedral structure particles with rough textures on the surface, and the composite nano-particles have the effects of slowly releasing bioactive substances, improving the inflammatory microenvironment and regulating and controlling osteogenesis under certain conditions. The composite nano-particle comprises curcumin powder and a ZIF-67 nano-material, the ZIF-67 nano-material can be decomposed to quickly release Co < 2 + >, macrophages are regulated and controlled to be polarized to an M2 type, and excessive immune inflammation reaction is improved; the curcumin powder is slowly released, so that the periodontal ligament stem cells can be regulated and controlled to be differentiated into osteoblasts, and the osteogenic activity is enhanced.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention discloses a functional hydrogel microsphere and a preparation method and application thereof, and relates to the technical field of medicines.The preparation method comprises the steps that a hyaluronic acid methacrylic acid precursor solution and an IL-1beta shRNA adenovirus stock solution are mixed to obtain an Ad-atHAMA precursor solution; preparing the Ad (at) HAMA precursor solution through an oil-in-water micro-fluidic technology to obtain an Ad (at) HAMA microsphere; and sequentially adding the Ad (at) HAMA microspheres, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide into a 2-morpholinoethanesulfonic acid buffer solution, carrying out activating treatment, adding E selectin, and incubating to obtain the functionalized hydrogel microspheres. The functionalized hydrogel microspheres can inhibit a related mechanism of acute spinal cord injury pathological progress and promote neural function repair by targeting adsorption of neutrophil to regulate Nets-triggered innate immune inflammation cascade.

The invention relates to a construction method and application of a loneliness mouse model, and the method comprises the steps: placing an experimental mouse in an isolation region in a transparent acrylic isolation cover through an environment in which physical isolation and social deprivation stimulation coexist, forming a visually accessible but physically isolated social environment with five normal living mice, and continuously inducing chronic loneliness for 4 weeks. The effectiveness of the model is verified through a multi-dimensional evaluation system, including behavioristics (open field, elevated maze and three-box experiment), neuroendocrine (serum noradrenaline and angiotensin II), immune inflammatory factors (IL-1beta, IL-6, TNF-alpha and CCL5) and nerve activation (blue spot, almond nucleus, lateral nucleus septum, medial prefrontal cortex and center joint dorsal nucleus C-Fos staining) indexes. According to the intervention method, dynamic environment abundance and social stimulation are adopted, running wheels are arranged, a modular abundance device is arranged, and a social environment of new mice is introduced, so that pathological phenotypes caused by loneliness are reversed. And a systematic experiment tool is provided for exploring association of aloneness and diseases.

Provided in the present invention are an anti-TLR7 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition thereof. The antibody or the antigen-binding fragment thereof can specifically bind to a human or simian TLR7 antigen and does not bind to murine TLR7, exhibits significant TLR7 antigen-binding activity, and can effectively inhibit various inflammatory cytokines produced upon TLR7 activation. The anti-TLR7 antibody or the antigen-binding fragment thereof can be used, either as a monotherapy or in combination with other drugs, for treating and / or preventing diseases pathologically associated with the TLR7 target, including immune inflammation-related diseases, allergic diseases, infectious diseases, cancers, etc.

The application discloses a construction method of a fat-targeted gene therapy vector. The method comprises the following steps: obtaining a fat tissue-specific promoter sequence; obtaining a shRNA coding sequence targeting a Tks4 gene; cloning the promoter sequence and the shRNA coding sequence into an adeno-associated virus vector skeleton to construct a recombinant expression vector; and co-transfecting the recombinant expression vector and an auxiliary plasmid into a packaging cell to package and purify a recombinant adeno-associated virus particle. The vector constructed by the application adopts an adiponectin promoter to drive the expression of miR30-shRNA targeting the Tks4, and can be specifically expressed in fat tissues and livers after being injected through a tail vein, significantly inhibits fat cell hypertrophy and systemic fat accumulation induced by a high-fat diet, reduces the serum cholesterol level, does not cause an immune inflammatory reaction, does not affect sugar metabolism, and is not expressed in non-target tissues. The application provides a safe and efficient new strategy for the gene therapy of obesity, hyperlipidemia, fatty liver and related metabolic diseases.

This application discloses the use of a biomarker in the preparation of a product for the treatment and prediction of myasthenia gravis, wherein the biomarker is one or more of OSM, CASP-8, TRAIL, TGF-α, FLT3L, IFN-γ, IL-7, and AXIN1. Through multi-omics combined analysis, this application explores the dynamic changes and molecular mechanisms of immune-inflammatory-related proteins after complement inhibition from the dual dimensions of gene transcription and protein expression, and finds a comprehensive biomarker that can systematically evaluate the dynamics of symptom improvement and the degree of disease stability, with the advantages of accurately guiding treatment adjustments and predicting disease outcomes.

The invention provides an anti-TLR7 antibody or an antigen binding fragment and a pharmaceutical composition thereof, the antibody or the antigen binding fragment thereof can be specifically bound with a human or monkey TLR7 antigen and is not bound with mouse TLR7, has remarkable TLR7 antigen binding activity, and can effectively inhibit various inflammatory cytokines generated by TLR7 activation. The anti-TLR7 antibody or the antigen binding fragment thereof can be used as a single agent or a drug combination and can be used for treating and / or preventing diseases related to TLR7 target pathology, including immune inflammation related diseases, allergic diseases, infectious diseases or cancers and the like.

The present invention provides novel drug-linker conjugates and antibody-drug conjugates of imidazo quinoline amine derivatives, which have agonistic activity against Toll-like receptors (TLRs), in particular TLR7 and / or TLR8, also provided are pharmaceutical compositions and methods of treatment against certain diseases or conditions mediated by or associated with TLR7 and / or TLR8 (e.g., graft rejection, autoimmunity, inflammation, allergy, asthma, infection, sepsis, cancer, and immunodeficiency).

The invention provides a skin repairing composition for relieving red, itching and dry symptoms of sensitive skin and application, and belongs to the technical field of cosmetics. The composition comprises an effective amount of an extract of at least two algae selected from the group consisting of Phaeodactylum tricornutum, Spirulina, Chlorella and Micrococcus, and optionally comprises other skin repair ingredients cooperating therewith. The skin repair composition for relieving red, itching and dry symptoms of sensitive skin simultaneously and synergistically intervenes four major causes of sensitive skin formation, namely barrier damage, hyperneurosis, immune inflammation and micro-ecological imbalance, breaks vicious circle and establishes a repair closed loop by utilizing the multiple effects of specific algae active ingredients, and has the effects of relieving the symptoms of red, itching and dry symptoms of sensitive skin and relieving the symptoms of red, itching and dry symptoms of sensitive skin. Therefore, the problems of red skin, itching skin, dry skin and the like are radically relieved.

The present invention discloses a novel aporphine compound, its preparation method and applications, and its structural formula is shown as follows. The name of the novel aporphine compound is 2-methoxy-9-hydroxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline (III 11 ). In the present invention: ① By using the computer-aided drug design method in the forefront field of pharmacy, this compound is designed according to the binding requirements of the drug action target; ② This compound is synthesized from 3-methoxyphenethylamine and 2-bromo-5-hydroxybenzaldehyde, and its preparation method is simple; ③ This compound is an aryl hydrocarbon receptor (AhR) agonist and an inducer for the generation of regulatory T cells (Treg cells), and can be used for the prevention and treatment of immune inflammation and related diseases. ④ This compound shows good plasma protein binding rate and bioavailability, and has good prospects for drug development. #imgabs0#

The present invention belongs to the field of biomedical technology, and particularly relates to the use of dendritic cells in the prevention and / or treatment of demyelinating diseases. The expression level of Talin1 protein in the dendritic cells is reduced or not expressed. Loading the dendritic cells with myelin peptides can safely and effectively alleviate immune inflammation and nerve damage, and thus is expected to develop into a new therapy for the prevention and / or treatment of demyelinating diseases.

The invention discloses a fracture risk prediction method and system, and relates to the technical field of health management. According to the prediction method, serious sarcopenia is selected to diagnose and assess the sarcopenia state, the ratio of monocytes to lymphocytes reflects the immune inflammation level, the prediction model is constructed in combination with the femoral neck bone mineral density T value, and the fracture risk influence factors are comprehensively covered; and the risk identification capability on special high-risk groups with sarcopenia, immune dysfunction and the like is effectively improved. And secondly, only three target independent variables are selected, and the three target independent variables are indexes which can be directly obtained or simply calculated in clinical routine examination, so that the data collection difficulty is greatly reduced. Meanwhile, the prediction model is visualized through a column diagram, complex calculation is not needed, a clinician can quickly inquire the fracture risk score through the actual value of the target subject, and the method is suitable for being efficiently applied to conventional outpatient service, hospitalization and other scenes.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of LAP3 and an agonist thereof in macrophage immune inflammation mediated diseases. The invention provides application of leucine aminopeptidase 3 or leucine aminopeptidase 3 agonist substances in preparation of drugs for prevention, treatment and / or adjuvant treatment of macrophage immune inflammation mediated diseases. According to the invention, it is found for the first time that the expression level of LAP3 in macrophages is increased under an acute stress condition, and the limiting effect of LAP3 on generation and development of sepsis and acute hepatitis is disclosed; the invention discloses that the knockout of the LAP3 can remodel a macrophage metabolic network, reduce oxidative phosphorylation, promote ROS (reactive oxygen species) production and activate TAK1, thereby promoting the activation of a downstream inflammation signal channel and finally promoting macrophage inflammation. A new target spot and a theoretical basis can be provided for clinical diagnosis and treatment of macrophage-mediated inflammation by illuminating the effect of LAP3 on regulating and controlling macrophage inflammation and a molecular mechanism of LAP3.

The invention discloses an S3B polypeptide taking SHP2 as an action target and application of the S3B polypeptide in treatment of tumors and inflammations. The amino acid sequence of the polypeptide is RLLREEEYVAPPRGPLPTLQVVPL, the amino acid sequence of a cell-penetrating peptide contained in the polypeptide is TAT: YGRKKRRQRRR, the polypeptide can enter cells after being wrapped by lipidosome, the effects of inhibiting proliferation, migration, growth and the like of tumor cells are achieved by inhibiting QPCTL enzyme activity and promoting SHP2 protein degradation, and then the purpose of treating diseases such as tumors is achieved. The invention provides a certain reference for treating SHP2 related tumors or immune inflammatory diseases and developing a novel SHP2 degradation drug.

According to the application of a reagent for detecting the biomarker in preparation of a xerophthalmia diagnosis and typing detection reagent, the galectin-9 plays an important role in the occurrence and development process of the xerophthalmia, the expression level of the galectin-9 has a certain correlation with the severity of the xerophthalmia, and the galectin-9 is expected to be used as the biomarker for diagnosis and treatment of the xerophthalmia and can be used for preparing the xerophthalmia diagnosis and typing detection reagent. By detecting the expression condition of Galectin-9 in tears, early and accurate diagnosis of the dry eye and quantitative evaluation of the disease degree are achieved, in addition, Galectin-9 expressed on T cells plays an important role in immune inflammation of the dry eye, ocular surface damage of the dry eye can be relieved by locally intervening Galectin-9 through conjunctiva, and Galectin-9 serves as a novel potential target and has a good application prospect. A new way is opened up for diagnosis and treatment of xerophthalmia, a therapeutic drug or an intervention means developed for Galectin-9 can regulate immune response, inhibit inflammatory response, improve tear secretion and the like from the etiological level, and an existing xerophthalmia treatment mode is expected to be changed, so that the treatment effect is improved, the prognosis of a patient is improved, and the clinical application prospect is broad. The application prospect in the field of diagnosis and treatment of the xerophthalmia is wide, and a certain significance is achieved for improving the overall prevention and treatment level of the xerophthalmia.

This invention discloses a method, system, and medium for dynamic prediction of pregnancy complications in SLE patients, belonging to the field of medical information technology. It aims to solve the technical problems of existing risk assessment methods, such as the inability to effectively integrate multi-dimensional time-series data and the lack of causal mechanism analysis of the dynamic evolution of risk, resulting in biased, delayed, and clinically inoperable prediction results. The method includes the following steps: S1: Acquiring multimodal health data of the target patient during pregnancy as a time series; S2: Based on the multimodal health data, constructing and updating a dynamic patient profile reflecting the patient's psychosocial state, immune inflammatory activity, and target organ function; S3: Inputting the dynamic patient profile into a trained risk prediction model. This invention, by constructing a dynamic patient profile and employing a time-series deep learning model for risk prediction, achieves a comprehensive, dynamic, and mechanistically transparent risk assessment of pregnancy complications in SLE patients.

The present invention discloses an extracellular matrix / glycopeptide hydrogel for heart failure treatment and its preparation method. The specific components of the hydrogel include cardiomyocyte extracellular matrix, polysaccharide and functional polypeptide. The hydrogel obtained by the present invention has a composition and structure imitating the extracellular matrix, can long-term replace the extracellular matrix of damaged tissues, and provide a microenvironment for cell survival, infiltration and proliferation; the extracellular matrix / glycopeptide hydrogel of the present invention has good injectability, can be directly injected into the myocardium, has good mechanical support characteristics, and has bioactivities of regulating immune inflammatory response and promoting angiogenesis, regulating cardiac remodeling and alleviating the heart failure process.

The invention discloses a layered microneedle patch as well as a preparation method and application thereof, and belongs to the field of biological medicines. Wherein the needle body tip is composed of a therapeutic agent and L-arginine shell modified glycan gel, has excellent biocompatibility and free DNA removal ability, and can deliver deferoxamine and synergistically regulate and control inflammation signals; the upper part of the needle body and the substrate are made of low-molecular-weight hyaluronic acid which is quickly dissolved after being in contact with skin, so that the needle tip is quickly separated from the substrate, the needle tip is retained at a diseased region, and effective deposition of a medicine at the diseased region is ensured; the layered microneedle can slowly release deferoxamine through pH response so as to inhibit ferroptosis; the modified chitosan can efficiently remove free DNA so as to reduce immune inflammation and cooperatively block immune inflammation circulation. The preparation process of the layered microneedle is controllable, the material biocompatibility is excellent, and the layered microneedle has the advantages of efficient targeted delivery, long-acting release and synergistic treatment, so that a feasible strategy is provided for psoriasis treatment.

The application belongs to the technical field of biological medicine, and particularly relates to a binding molecule targeting CCL5 and application of the binding molecule in combination with drugs in treatment of Th2-type inflammation related diseases. The application discloses use of a binding molecule targeting CCL5 or a pharmaceutical composition comprising the binding molecule in preparation of a product having one or more of the following functions: 1) prevention and / or treatment of Th2-type inflammation related diseases; 2) reduction of skin lesion tissue thickness; 3) reduction of clinical score of atopic dermatitis; 4) reduction of scratching behavior; 5) reduction of tissue damage; 6) alleviation of inflammatory reaction and inhibition of expression of inflammatory factors; and 7) reduction of inflammatory cell infiltration. The binding molecule targeting CCL5 or the pharmaceutical composition comprising the binding molecule has important value in prevention and treatment of immune inflammatory diseases such as atopic dermatitis, allergic rhinitis, asthma, food allergy or drug allergy.

The invention discloses a construction method of a sensitive skin animal model, and belongs to the technical field of animal model construction. According to the method disclosed by the invention, the sensitive skin animal model is constructed by smearing the lauryl sodium sulfate on the back skin of the mouse after hair removal in combination with veratrine or capsaicin, so that physiological indexes of human sensitive skin can be simulated; key pathological processes of human sensitive skin can be simulated by detecting key pathological indexes such as skin barrier damage, nerve and blood vessel high reactivity, immune inflammation and the like, natural pathophysiological processes of human sensitive skin can be simulated, and pathogenesis of sensitive skin is basically covered; barrier destruction of mouse skin, high reactivity of nerve and blood vessels and inflammatory response are induced, and clinical practice is met. In addition, the method is good in repeatability, high in safety and easy and convenient to operate, sensitive skin medicine screening and personalized treatment scheme development can be promoted, the research and development period of sensitive skin related treatment schemes is shortened, and the application prospect is good.

The invention discloses an application of KL-6 alone or in combination with other immune inflammation markers in complex silicosis recognition and lung function injury evaluation. The invention firstly discloses application of KL-6 in preparation of a product for complex silicosis identification and lung function injury evaluation. The invention further discloses application of the KL-6 combined with other immune inflammation markers in preparation of products for complex silicosis recognition and lung function injury evaluation. According to the invention, KL-6 is taken as a core, LDH and ESR are combined to construct a diagnosis scheme, and complex silicosis and dust exposed persons or simple silicosis can be distinguished; meanwhile, KL-6 is in significant negative correlation with lung function parameters and can assist in evaluating the severity of diseases and the condition of lung function impairment. The method is rapid and accurate in diagnosis, easy and convenient to operate, controllable in cost, capable of achieving batch detection, suitable for health monitoring of high-risk occupational people and capable of providing efficient technical support for early recognition of complex silicosis, lung function injury evaluation and clinical decision making.

The invention discloses a model for early prediction of acute kidney injury risk after geriatric sepsis patients are transferred into ICU based on clinical variables and immune inflammation indexes, 627 geriatric sepsis patients are included in the research, and the clinical variables and immune inflammation indexes of the geriatric sepsis patients in the ICU within 24 hours are collected; clinical variables of the first 6 ranked and immune inflammation indexes of the first 4 ranked related to acute kidney injury are screened out, prediction models are constructed through four machine learning algorithms respectively, the model prediction performance of the XGBoost algorithm is the best, the model prediction performance of the logistic regression algorithm is the second, and the model prediction performance of the XGBoost algorithm is the best. And a visual column diagram is made according to a logistic regression algorithm, and an early prediction model with good accuracy is established.

The present disclosure provides antibodies that bind to CD40, and methods of using them to modulate immunity in a patient in need thereof and to treat autoimmune disorders or immunoinflammatory disorders.

The application discloses a kind of S3B polypeptide with SHP2 as action target point and its application in treating tumor and inflammation.The amino acid sequence of the polypeptide is RLLREEEYVAPPRGPLPTLQVVPL, the amino acid sequence of transmembrane peptide included in the polypeptide is TAT:YGRKKRRQRRR, the polypeptide can enter cell after being wrapped by liposome, inhibits QPCTL enzyme activity, promotes the degradation of SHP2 protein, thereby playing the role of inhibiting tumor cell proliferation, migration and growth, etc., to achieve the purpose of treating tumor and other diseases.The application provides a certain reference for treating SHP2 related tumor or immune inflammatory disease and developing new SHP2 degradation drug.

This invention discloses the application of C5aR1 antagonists and / or IL-1β inhibitors in the preparation of drugs for treating congenital heart disease with pulmonary hypovascularity. This invention breaks through the limitations of traditional single surgical procedures, providing for the first time a targeted, effective, and safe drug treatment strategy from a novel perspective of immune inflammation regulation. This strategy not only effectively promotes lung development and improves patients' physiological indicators, but also safeguards high-risk surgeries, ultimately comprehensively improving the prognosis and quality of life for patients with congenital heart disease with pulmonary hypovascularity.

The invention relates to a bilobalide A modified polycaprolactone nanofiber membrane as well as a preparation method and application thereof, and relates to the technical field of composite biological materials. The nanofiber membrane is prepared from the following components: polycaprolactone and bilobalide A. The invention further discloses a preparation method of the nanofiber membrane. The bilobalide A is modified on the polycaprolactone nanofiber membrane through an electrostatic spinning technology, and the obtained functional bilobalide A modified polycaprolactone nanofiber membrane increases the hydrophilicity of polycaprolactone, promotes cell adhesion and inhibits generation of macrophages and inflammatory factors; after being implanted in a body wrapping the tissue-engineered cartilage, the material can inhibit immune inflammatory response of the tissue-engineered cartilage, maintain the form of the engineered cartilage and promote cartilage regeneration.